Vaidyasaneayurvedlaborat earnings calls.

Vaidya Sane Ayurved Laboratories reported FY26 revenue of ₹106.91 CrCurrent reported value: ₹106.91 Cr. No comparable prior figure is available in the source record. (up 18.9Current reported value: 18.9. No comparable prior figure is available in the source record.% YoY) driven by patient volume growth and improved product mix. EBITDA declined 152bps YoY to 14.4Current reported value: 14.4. No comparable prior figure is available in the source record.% margin due to a new call center (₹50-60 lakh/month) and elevated marketing spend in H2, though management expects margins to recover toward 20% by FY28. The strategic shift from preventive wellness to higher-value disease reversal programs (₹50-60K annual billing vs ₹10-13K) is improving unit economics. Hospital capacity expansion to 250-300 beds by March 2027 (from current ~120 operationalCurrent ~120 operational. Reported change: +130-180 beds by Mar-27.) and the Paras Healthcare acquisition (70 franchise clinics, ₹14 Cr revenue) provide near-term growth drivers. However, franchise count has stagnated at ~180-190 over 3 years, and care plan conversions declined to 28-29K from 33.3K in FY25, raising execution questions. The FY27 revenue guidance of ₹170-180 Cr implies ~60% growth, requiring significant acceleration.